M&R Capital Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,635 shares of the company’s stock after selling 811 shares during the quarter. Johnson & Johnson makes up about 1.1% of M&R Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest holding. M&R Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,837,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $4,609,399,000. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC boosted its holdings in shares of Johnson & Johnson by 161,420.2% during the second quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after acquiring an additional 7,271,978 shares during the period. Finally, Providence Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares during the period. 68.40% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
JNJ has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 price target on shares of Johnson & Johnson in a report on Friday, December 1st. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 26th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.75.
Read Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
JNJ stock opened at $156.46 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a one year low of $144.95 and a one year high of $180.93. The firm has a market capitalization of $376.64 billion, a PE ratio of 11.62, a P/E/G ratio of 3.17 and a beta of 0.57. The firm has a 50-day moving average of $152.51 and a two-hundred day moving average of $159.79.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The company had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. On average, analysts forecast that Johnson & Johnson will post 9.97 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is 35.34%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.